Bausch Health Companies (NYSE:BHC) Posts Earnings Results, Misses Expectations By $0.44 EPS

Bausch Health Companies (NYSE:BHC - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $1.21 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44), Zacks reports. The firm had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 650.39% and a negative net margin of 0.48%. Bausch Health Companies updated its FY 2025 guidance to EPS.

Bausch Health Companies Stock Up 1.7 %

Shares of BHC traded up $0.13 during mid-day trading on Friday, hitting $7.31. The company had a trading volume of 3,004,609 shares, compared to its average volume of 3,096,627. The stock has a market cap of $2.64 billion, a PE ratio of -60.87, a P/E/G ratio of 0.38 and a beta of 0.68. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $11.46. The business's 50-day simple moving average is $7.35 and its 200-day simple moving average is $7.48.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. StockNews.com upgraded shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a report on Friday, October 25th. Royal Bank of Canada cut their price target on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a report on Thursday, January 30th. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.